Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile - PubMed (original) (raw)

Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile

T Norén et al. Antimicrob Agents Chemother. 2007 May.

Abstract

In silico, we identified fusA (2,067 bp) in Clostridium difficile 630. Sequencing of fusA in posttherapy fusidic acid-resistant C. difficile isolates from 12 patients with C. difficile-associated diarrhea (CDAD) identified fusA mutations, one or two nonsynonymous substitutions, or in one case a deletion of one codon associated with resistance. Five of these mutations have previously been described in fusA of fusidic acid-resistant Staphylococcus aureus, but seven were novel fusA mutations. Fusidic acid monotherapy for CDAD seemed to rapidly select conserved resistant mutants.

PubMed Disclaimer

Similar articles

• Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.
  Norén T, Wullt M, Akerlund T, Bäck E, Odenholt I, Burman LG. Norén T, et al. Antimicrob Agents Chemother. 2006 Sep;50(9):3028-32. doi: 10.1128/AAC.00019-06. Antimicrob Agents Chemother. 2006. PMID: 16940098 Free PMC article. Clinical Trial.
• Mutations in rpoB and fusA cause resistance to rifampicin and fusidic acid in methicillin-resistant Staphylococcus aureus strains from a tertiary hospital in Malaysia.
  Lim KT, Teh CS, Yusof MY, Thong KL. Lim KT, et al. Trans R Soc Trop Med Hyg. 2014 Feb;108(2):112-8. doi: 10.1093/trstmh/trt111. Epub 2013 Dec 13. Trans R Soc Trop Med Hyg. 2014. PMID: 24336696
• A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates.
  O'Neill AJ, Larsen AR, Henriksen AS, Chopra I. O'Neill AJ, et al. Antimicrob Agents Chemother. 2004 Sep;48(9):3594-7. doi: 10.1128/AAC.48.9.3594-3597.2004. Antimicrob Agents Chemother. 2004. PMID: 15328136 Free PMC article.
• Characterization of global patterns and the genetics of fusidic acid resistance.
  Farrell DJ, Castanheira M, Chopra I. Farrell DJ, et al. Clin Infect Dis. 2011 Jun;52 Suppl 7:S487-92. doi: 10.1093/cid/cir164. Clin Infect Dis. 2011. PMID: 21546625 Review.
• Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
  Howden BP, Grayson ML. Howden BP, et al. Clin Infect Dis. 2006 Feb 1;42(3):394-400. doi: 10.1086/499365. Epub 2005 Dec 15. Clin Infect Dis. 2006. PMID: 16392088 Review.

Cited by

• Effect of Ferredoxin Receptor FusA on the Virulence Mechanism of Pseudomonas plecoglossicida.
  He R, Wang J, Lin M, Tian J, Wu B, Tan X, Zhou J, Zhang J, Yan Q, Huang L. He R, et al. Front Cell Infect Microbiol. 2022 Mar 22;12:808800. doi: 10.3389/fcimb.2022.808800. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35392610 Free PMC article.
• Origin, genomic diversity and microevolution of the Clostridium difficile B1/NAP1/RT027/ST01 strain in Costa Rica, Chile, Honduras and Mexico.
  Guerrero-Araya E, Meneses C, Castro-Nallar E, Guzmán D AM, Álvarez-Lobos M, Quesada-Gómez C, Paredes-Sabja D, Rodríguez C. Guerrero-Araya E, et al. Microb Genom. 2020 May;6(5):e000355. doi: 10.1099/mgen.0.000355. Epub 2020 Mar 16. Microb Genom. 2020. PMID: 32176604 Free PMC article.
• Antimicrobial Resistance in Clostridium and Brachyspira spp. and Other Anaerobes.
  Archambault M, Rubin JE. Archambault M, et al. Microbiol Spectr. 2020 Jan;8(1):10.1128/microbiolspec.arba-0020-2017. doi: 10.1128/microbiolspec.ARBA-0020-2017. Microbiol Spectr. 2020. PMID: 31971162 Free PMC article. Review.
• Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.
  Peng Z, Jin D, Kim HB, Stratton CW, Wu B, Tang YW, Sun X. Peng Z, et al. J Clin Microbiol. 2017 Jul;55(7):1998-2008. doi: 10.1128/JCM.02250-16. Epub 2017 Apr 12. J Clin Microbiol. 2017. PMID: 28404671 Free PMC article. Review.
• Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.
  Leeds JA. Leeds JA. Cold Spring Harb Perspect Med. 2016 Feb 1;6(2):a025445. doi: 10.1101/cshperspect.a025445. Cold Spring Harb Perspect Med. 2016. PMID: 26834162 Free PMC article. Review.

References

1. 1. Besier, S., A. Ludwig, V. Brade, and T. A. Wichelhaus. 2003. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol. Microbiol. 47463-469. - PubMed
2. 1. Brown, E. M., and P. Thomas. 2002. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 359803. - PubMed
3. 1. Bruggemann, H., S. Baumer, W. F. Fricke, A. Wiezer, H. Liesegang, I. Decker, C. Herzberg, R. Martinez-Arias, R. Merkl, A. Henne, and G. Gottschalk. 2003. The genome sequence of Clostridium tetani, the causative agent of tetanus disease. Proc. Natl. Acad. Sci. USA 1001316-1321. - PMC - PubMed
4. 1. Burdon, D. W., J. D. Brown, D. J. Youngs, Y. Arabi, N. Shinagawa, J. Alexander-Williams, M. R. Keighley, and R. H. George. 1979. Antibiotic susceptibility of Clostridium difficile. J. Antimicrob. Chemother. 5307-310. - PubMed
5. 1. Cronberg, S., B. Castor, and A. Thoren. 1984. Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection 12276-279. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc